Clinical management of diabetic foot infection: diagnostics, therapeutics and the future

References

• Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care26(5), 1435–1438 (2003).
   PubMed Web of Science ®Google Scholar
• Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care29(6), 1288–1293 (2006).
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet366(9498), 1719–1724 (2005).
   PubMed Web of Science ®Google Scholar
• Price P. The diabetic foot: quality of life. Clin. Infect. Dis.39(Suppl. 2), S129–S131 (2004).
   PubMed Web of Science ®Google Scholar
• Carmona GA, Hoffmeyer P, Herrmann FR et al. Major lower limb amputations in the elderly observed over ten years: the role of diabetes and peripheral arterial disease. Diabetes Metab.31(5), 449–454 (2005).
   PubMed Web of Science ®Google Scholar
• Lipsky BA. Medical treatment of diabetic foot infections. Clin. Infect. Dis.39(Suppl. 2), S104–S114 (2004).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Berendt AR, Deery HG et al. Diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis.39(7), 885–910 (2004).
   PubMed Web of Science ®Google Scholar
• Falanga V. Wound healing and its impairment in the diabetic foot. Lancet366(9498), 1736–1743 (2005).
   PubMed Web of Science ®Google Scholar
• Zykova SN, Jenssen TG, Berdal M, Olsen R, Myklebust R, Seljelid R. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic Type II-like db/db mice. Diabetes49(9), 1451–1458 (2000).
   PubMed Web of Science ®Google Scholar
• Rich J, Lee JC. The pathogenesis of Staphylococcus aureus infection in the diabetic NOD mouse. Diabetes54(10), 2904–2910 (2005).
   PubMed Web of Science ®Google Scholar
• Tentolouris N, Petrikkos G, Vallianou N et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin. Microbiol. Infect.12(2), 186–189 (2006).
   PubMed Web of Science ®Google Scholar
• Kessler L, Piemont Y, Ortega F et al. Comparison of microbiological results of needle puncture vs superficial swab in infected diabetic foot ulcer with osteomyelitis. Diabet. Med.23(1), 99–102 (2006).
   PubMed Web of Science ®Google Scholar
• Abdulrazak A, Bitar ZI, Al-Shamali AA, Mobasher LA. Bacteriological study of diabetic foot infections. J. Diabetes Complications19(3), 138–141 (2005).
   PubMed Web of Science ®Google Scholar
• Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet. Med.20(2), 159–161 (2003).
   PubMed Web of Science ®Google Scholar
• Lew DP, Waldvogel FA. Osteomyelitis. N. Engl. J. Med.336(14), 999–1007 (1997).
   PubMed Web of Science ®Google Scholar
• Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin. Infect. Dis.39(Suppl. 2), S115–S122 (2004).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet366(9498), 1695–1703 (2005).
   PubMed Web of Science ®Google Scholar
• Hartemann-Heurtier A, Robert J, Jacqueminet S et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet. Med.21(7), 710–715 (2004).
   PubMed Web of Science ®Google Scholar
• King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med.144(5), 309–317 (2006).
   PubMed Web of Science ®Google Scholar
• Holtom PD, Zamorano D, Patzakis MJ. Osteomyelitis attributable to vancomycin-resistant enterococci. Clin. Orthop. Relat. Res.2002(403), 38–44 (2002).
   Google Scholar
• Appelbaum PC. MRSA – the tip of the iceberg. Clin. Microbiol. Infect.12(Suppl. 2), 3–10 (2006).
   PubMed Web of Science ®Google Scholar
• Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med.348(14), 1342–1347 (2003).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin. Infect. Dis.42(1), 37–45 (2006).
   PubMed Web of Science ®Google Scholar
• Nelson EA, O’Meara S, Craig D et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol. Assess.10(12), 1–238 (2006).
   Google Scholar
• Schinabeck MK, Johnson JL. Osteomyelitis in diabetic foot ulcers. Prompt diagnosis can avert amputation. Postgrad. Med.118(1), 11–15 (2005).
   PubMed Web of Science ®Google Scholar
• Tan PL, Teh J. MRI of the diabetic foot: differentiation of infection from neuropathic change. Br. J. Radiol. DOI: 0: 30036666v1 (2006) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Berendt AR, Lipsky B. Is this bone infected or not? Differentiating neuro-osteoarthropathy from osteomyelitis in the diabetic foot. Curr. Diab. Rep.4(6), 424–429 (2004).
   PubMedGoogle Scholar
• Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet366(9498), 1725–1735 (2005).
   PubMed Web of Science ®Google Scholar
• Armstrong DG, Lavery LA, Sariaya M, Ashry H. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. J. Foot Ankle Surg.35(4), 280–283 (1996).
   PubMedGoogle Scholar
• Eneroth M, Larsson J, Apelqvist J. Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis. J. Diabetes Complications13(5–6), 254–263 (1999).
   PubMed Web of Science ®Google Scholar
• Redkar R, Kalns J, Butler W et al. Identification of bacteria from a non-healing diabetic foot wound by 16 S rDNA sequencing. Mol. Cell. Probes14(3), 163–169 (2000).
   PubMed Web of Science ®Google Scholar
• Rajbhandari SM, Sutton M, Davies C, Tesfaye S, Ward JD. ‘Sausage toe’: a reliable sign of underlying osteomyelitis. Diabet. Med.17(1), 74–77 (2000).
   PubMed Web of Science ®Google Scholar
• Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA.273(9), 721–723 (1995).
   PubMed Web of Science ®Google Scholar
• Senneville E, Melliez H, Beltrand E et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin. Infect. Dis.42(1), 57–62 (2006).
   PubMed Web of Science ®Google Scholar
• Zuluaga AF, Galvis W, Saldarriaga JG, Agudelo M, Salazar BE, Vesga O. Etiologic diagnosis of chronic osteomyelitis: a prospective study. Arch. Intern. Med.166(1), 95–100 (2006).
   PubMedGoogle Scholar
• Williams DT, Hilton JR, Harding KG. Diagnosing foot infection in diabetes. Clin. Infect. Dis.39(Suppl. 2), S83–S86 (2004).
   PubMed Web of Science ®Google Scholar
• Ledermann HP, Morrison WB. Differential diagnosis of pedal osteomyelitis and diabetic neuroarthropathy: MR Imaging. SeminMusculoskelet. Radiol.9(3), 272–283 (2005).
   PubMed Web of Science ®Google Scholar
• Chatha DS, Cunningham PM, Schweitzer ME. MR imaging of the diabetic foot: diagnostic challenges. Radiol. Clin. North Am.43(4), 747–759 (2005).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Berendt AR, Embil J, De Lalla F. Diagnosing and treating diabetic foot infections. Diabetes Metab. Res. Rev.20(Suppl. 1), S56–S64 (2004).
   PubMed Web of Science ®Google Scholar
• Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab. Res. Rev.20(Suppl. 1), S90–S95 (2004).
   PubMed Web of Science ®Google Scholar
• Robson MC, Steed DL, Franz MG. Wound healing: biologic features and approaches to maximize healing trajectories. Curr. Probl. Surg.38(2), 72–140 (2001).
   PubMed Web of Science ®Google Scholar
• Senneville E. Antimicrobial interventions for the management of diabetic foot infections. Expert Opin. Pharmacother.6(2), 263–273 (2005).
   PubMed Web of Science ®Google Scholar
• Nelson EA, O’Meara S, Golder S, Dalton J, Craig D, Iglesias C. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet. Med.23(4), 348–359 (2006).
   PubMed Web of Science ®Google Scholar
• Harkless L, Boghossian J, Pollak R et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg. Infect. (Larchmt.)6(1), 27–40 (2005).
   PubMedGoogle Scholar
• Legat FJ, Krause R, Zenahlik P et al. Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection. Antimicrob. Agents Chemother.49(10), 4368–4371 (2005).
   PubMed Web of Science ®Google Scholar
• Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs65(15), 2151–2178 (2005).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch. Intern. Med.150(4), 790–797 (1990).
   PubMedGoogle Scholar
• Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy25(2), 253–264 (2005).
   PubMed Web of Science ®Google Scholar
• Edmiston CE, Krepel CJ, Seabrook GR et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob. Agents Chemother.48(3), 1012–1016 (2004).
   PubMed Web of Science ®Google Scholar
• Muller M, Brunner M, Hollenstein U et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob. Agents Chemother.43(8), 2056–2058 (1999).
   PubMed Web of Science ®Google Scholar
• Oberdorfer K, Swoboda S, Hamann A et al. Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J. Antimicrob. Chemother.54(4), 836–839 (2004).
   PubMed Web of Science ®Google Scholar
• Edmiston CE Jr, Krepel CJ, Kehl KS et al. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J. Antimicrob. Chemother.56(5), 872–878 (2005).
   PubMed Web of Science ®Google Scholar
• Senneville E, Yazdanpanah Y, Cazaubiel M et al. Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J. Antimicrob. Chemother.48(6), 927–930 (2001).
   PubMed Web of Science ®Google Scholar
• Peppard WJ, Weigelt JA. Role of linezolid in the treatment of complicated skin and soft tissue infections. Expert Rev. Anti Infect. Ther.4(3), 357–366 (2006).
   PubMedGoogle Scholar
• McKinnon PS, Sorensen SV, Liu LZ, Itani KM. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann. Pharmacother.40(6), 1017–1023 (2006).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin. Infect. Dis.38(1), 17–24 (2004).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob. Agents Chemother.44(4), 1062–1066 (2000).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother.55(2), 240–245 (2005).
   PubMed Web of Science ®Google Scholar
• Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J. Chemother.17(6), 643–650 (2005).
   PubMed Web of Science ®Google Scholar
• Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin. Orthop. Relat. Res.2004(427), 67–71 (2004).
   Google Scholar
• Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004). Diagn. Microbiol. Infect. Dis.52(3), 195–201 (2005).
   PubMed Web of Science ®Google Scholar
• Livermore DM. Can β-lactams be re-engineered to beat MRSA? Clin. Microbiol. Infect.12(Suppl. 2), 11–16 (2006).
   PubMed Web of Science ®Google Scholar
• Legat FJ, Maier A, Dittrich P et al. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob. Agents Chemother.47(1), 371–374 (2003).
   PubMed Web of Science ®Google Scholar
• Stengel D, Gorzer E, Schintler M et al. Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin. J. Chemother.17(5), 527–535 (2005).
   PubMed Web of Science ®Google Scholar
• Armstrong DG, Lipsky BA. Advances in the treatment of diabetic foot infections. Diabetes Technol. Ther.6(2), 167–177 (2004).
   PubMedGoogle Scholar
• Roeder B, Van Gils CC, Maling S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J. Foot Ankle Surg.39(2), 124–130 (2000).
   PubMedGoogle Scholar
• Bergin SM, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database Syst. Rev. (1), CD005082 (2006).
   PubMedGoogle Scholar
• Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Agents24(6), 536–547 (2004).
   PubMed Web of Science ®Google Scholar
• Ge Y, MacDonald D, Henry MM et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn. Microbiol. Infect. Dis.35(1), 45–53 (1999).
   PubMed Web of Science ®Google Scholar
• Apelqvist J, Ragnarson-Tennvall G. Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine ointment and standard treatment. An economic analysis alongside a clinical trial. Acta Derm. Venereol.76(3), 231–235 (1996).
   PubMed Web of Science ®Google Scholar
• Tan JS. Foot infections in diabetic patients. Curr. Infect. Dis. Rep.6(5), 377–379 (2004).
   PubMedGoogle Scholar
• Sumpio BE, Lee T, Blume PA. Vascular evaluation and arterial reconstruction of the diabetic foot. Clin. Podiatr. Med. Surg.20(4), 689–708 (2003).
   PubMedGoogle Scholar
• Aksoy DY, Gurlek A, Cetinkaya Y et al. Change in the amputation profile in diabetic foot in a tertiary reference center: efficacy of team working. Exp. Clin. Endocrinol. Diabetes112(9), 526–530 (2004).
   PubMed Web of Science ®Google Scholar
• Armstrong DG, Salas P, Short B et al. Maggot therapy in ‘lower-extremity hospice’ wound care: fewer amputations and more antibiotic-free days. J. Am. Podiatr. Med. Assoc.95(3), 254–257 (2005).
   PubMed Web of Science ®Google Scholar
• Sherman RA. Maggot therapy for treating diabetic foot ulcers unresponsive to conventional therapy. Diabetes Care26(2), 446–451 (2003).
   PubMed Web of Science ®Google Scholar
• Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis. Diabetes Care28(2), 454–460 (2005).
   PubMed Web of Science ®Google Scholar
• Berendt AR. Counterpoint: hyperbaric oxygen for diabetic foot wounds is not effective. Clin. Infect. Dis.43(2), 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• Barnes RC. Point: hyperbaric oxygen is beneficial for diabetic foot wounds. Clin. Infect. Dis.43(2), 188–192 (2006).
   PubMed Web of Science ®Google Scholar
• Sweitzer SM, Fann SA, Borg TK, Baynes JW, Yost MJ. What is the future of diabetic wound care? Diabetes Educ.32(2), 197–210 (2006).
   PubMed Web of Science ®Google Scholar
• Saar WE, Lee TH, Berlet GC. The economic burden of diabetic foot and ankle disorders. Foot Ankle Int.26(1), 27–31 (2005).
   PubMed Web of Science ®Google Scholar
• Ragnarson-Tennvall G, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clin. Infect. Dis.39(Suppl 2), S132–S139 (2004).
   PubMed Web of Science ®Google Scholar
• Tennvall GR, Apelqvist J, Eneroth M. Costs of deep foot infections in patients with diabetes mellitus. Pharmacoeconomics18(3), 225–238 (2000).
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet. Med.20(6), 442–450 (2003).
   PubMed Web of Science ®Google Scholar